MedTrace Logo

Osteogenic Action of a Biphasic Bioceramic With Statin in a Third Molar Extraction Model

NCT06338241 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-04-03

No results posted yet for this study

Summary

The clinical study aims to assess the osteogenic effects of Galibone+ in bone regeneration post-extraction of impacted mandibular third molars.

Conditions

  • Bone Loss
  • Regenerative Inflammation

Interventions

COMBINATION_PRODUCT

Biphasic bioceramic of tricalcium phosphate and hydroxyapatite with simvastatin

The intervention description for Galibone+ in the study involves the application of this substance to promote bone regeneration following the extraction of impacted mandibular third molars. Galibone is indicated to treat segmental and cavity bone loss, aesthetic repairs and bone augmentations (such as inlay or onlay grafts); to fill dental alveolar bone; for the placement of dental implants; for the stabilization of osteotomies and prostheses in dentistry.

OTHER

Bovine Hydroxyapatite

The intervention description for Bio-Oss in the study involves the application of this standard material to promote bone regeneration following the extraction of impacted mandibular third molars. Bio-Oss is a commonly used xenograft material known for its osteoconductive properties.

Sponsors & Collaborators

  • Universidad de Murcia

    collaborator OTHER

  • Mario Pérez Sayáns

    lead OTHER

Principal Investigators

  • Abel García García, PhD, MD · Universidade de Santaiago de Compostela

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-02
Primary Completion
2025-06-02
Completion
2025-09-02

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06338241 on ClinicalTrials.gov